Starting sacubitril/valsartan (Entresto) for recently decompensated heart failure with ejection fraction (EF) over 40% improved a key prognostic marker and, for those in the 40-60% range, clinical ...

Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...

Q: I was recently diagnosed with mild heart failure. But my echocardiogram showed a normal ejection fraction. Why would I still have heart failure? A: Heart failure conjures up the image of your heart ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide improved HF symptoms and exercise capacity vs. placebo in patients with HFpEF and obesity, across ...

DALLAS, September 15, 2025 — The American Heart Association, a relentless force changing the future of health for everyone everywhere, is launching a new initiative to improve in-hospital care for ...

Prague, Czechia – 21 May 2023: Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilisation for worsening heart failure in patients with ...

The American Heart Association, a relentless force changing the future of health for everyone everywhere, is launching a new initiative to improve in-hospital care for people with heart failure with ...

Presenter: Christopher Fellows, MD, Virginia Mason Medical Center (Seattle, Washington) on behalf of the PAVE Study Group: LV based Cardiac Stimulation Post AV Nodal Ablation E valuation The ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...